Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26796924 | 1.00 | CTSL (0.31) | CTSLCTSSCTSKMRGPRX4RAB9A | |
| SCHEMBL26769804 | 0.87 | L3MBTL1 (0.37) | CTSLCTSSCTSK | |
| SCHEMBL20121313 | 0.84 | AKR1C3 (0.32) | MRGPRX4 | |
| SCHEMBL14211799 | 0.84 | AKR1C3 (0.32) | MRGPRX4 | |
| SCHEMBL18509333 | 0.81 | CYP1A2 (0.39) | CTSLCTSSCTSKRAB9A | |
| SCHEMBL26769871 | 0.81 | ALDH1A1 (0.38) | CTSLCTSSCTSK | |
| SCHEMBL26769845 | 0.81 | CYP1A2 (0.39) | CTSLCTSSCTSKRAB9A | |
| SCHEMBL17770803 | 0.81 | — | — | |
| SCHEMBL16852388 | 0.80 | FFAR4 (0.35) | CTSLCTSSCTSK | |
| SCHEMBL14289248 | 0.79 | L3MBTL1 (0.41) | MRGPRX4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9982194-B2 | Liquid-crystalline media | MERECK PATENT GMBH (DE) | 2018-05-29 | — | — | US | disclosed |
| US-20180119010-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2018-05-03 | — | — | US | disclosed |
| US-20170306232-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2017-10-26 | — | — | US | disclosed |
| US-9777216-B2 | Liquid crystalline medium | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2017-10-03 | — | — | US | disclosed |
| US-20170044436-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2017-02-16 | — | — | US | disclosed |
| US-20160208170-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2016-07-21 | — | — | US | disclosed |
| US-9347002-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2016-05-24 | — | — | US | disclosed |
| US-20150203758-A1 | LIQUID-CRYSTALLINE MEDIA | MERCK PATENT GMBH (DE) | 2015-07-23 | — | — | US | disclosed |
| US-20150036095-A1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2015-02-05 | — | — | US | disclosed |
| US-20140028964-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| US-20130207038-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-20130183460-A1 | LIQUID-CRYSTALLINE MEDIA | MERCK PATENT GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20120305843-A1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160208170-A1 | LIQUID-CRYSTALLINE MEDIUM | NEFM, VIM, PLG | CTSL 200/4885CTSS 141/4885CTSK 630/4885 |
| US-20120305843-A1 | LIQUID CRYSTALLINE MEDIUM | NEFM, VIM, PLG | CTSL 84/4885CTSS 72/4885CTSK 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.